XBCM urinary biomarker reduces cystoscopies by 55% in high-grade NMIBC surveillance without compromising recurrence detection safety.
Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal toxicity.
Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy Read More »
FDA approves mitomycin (Zusduri) for recurrent low-grade NMIBC: 78% complete response, 79% maintain response ≥12 months in ENVISION trial.
CR rates greater than 80% achieved with TAR-200 device – first time we’ve seen rates this high in BCG-unresponsive NMIBC patients.
XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV while reducing cystoscopy burden by 56% in high-grade NMIBC surveillance.
Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance Read More »
